Dynavax Technologies Corporation (NASDAQ:DVAX) is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.2 per share.
For the full year, analysts predict revenues of $ 35.30 million, while looking forward to loss of $ 1.12 per share.
Previous Quarter Performance
Dynavax Technologies Corporation posted loss for the second quarter of $ 0.53 per share, from the revenue of $ 2.67 million. The quarterly revenues reduced 67.83 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.24 per share from $ 5.55 million in revenue. The bottom line results missed street analysts by $ 0.29 or 120.83 percent, at the same time, top line results fell short of analysts by $ 2.88 million or 51.89 percent.
Stock Performance
Shares of Dynavax Technologies Corporation traded up $ 0.13 or 3.25 percent on Wednesday, reaching $ 4.13 with volume of 3.46 million shares. Dynavax Technologies Corporation has traded high as $ 4.36 and has cracked $ 3.98 on the downward trend
The closing price of $ 4.13, representing a 122.22 % increase from the 52 week low of $ 1.80 and a 67.85 % decrease over the 52 week high of $ 12.44.
The company has a market capital of $ 452.28 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Dynavax Technologies Corporation will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.dynavax.com
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the bodys innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Its product candidates include SD-101, a cancer immunotherapy that is in Phase 2 clinical trials; DV281, an investigational TLR9 agonist, which is in Phase I clinical trial for the treatment of non-small cell lung cancer; and AZD1419, which is in Phase IIa clinical trial to treat asthma.
